Follow-up and transition of care for low recurrence risk thyroid cancer patients in Canada
Authors:
- Ralf PaschkeRPRalf Paschke
- Sana GhaznaviSGSana Ghaznavi
- Syed Ali ImranSISyed Ali Imran
- Jennifer JacquierJJJennifer Jacquier
- Heather LochnanHLHeather Lochnan
- Marie-Hélène MassicotteMMMarie-Hélène Massicotte
- Elliot MitmakerEMElliot Mitmaker
- Deric MorrisonDMDeric Morrison
- Vicki MunroVMVicki Munro
- Michelle SveistrupMSMichelle Sveistrup
- Sam M. WisemanSWSam M. Wiseman
- Afshan ZahediAZAfshan Zahedi
Open Access
- 16 May 2025
- journal article
- guideline
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (3)
Abstract
The incidence of differentiated thyroid cancer (DTC) has increased significantly in recent decades. Following initial diagnosis, DTC patients are classified according to the American Thyroid Association (ATA) as low, intermediate, and high risk for recurrence. Patients in the ATA low recurrence-risk category have a recurrence risk of ≤5%, with 20-year disease-specific mortality of <1%. Accordingly, there has been a shift to de-escalating initial treatment, including the relaxation of thyroid-stimulating hormone suppression. In addition, fewer low-risk patients undergo total thyroidectomy or radioactive iodine therapy. However, the optimal long-term surveillance strategy remains unclear, with many patients continuing follow-up in speciality clinics for many years. In addition, emerging evidence suggests that long-term surveillance can be effectively managed in primary care settings. To enhance understanding among Canadian thyroid practitioners and to improve care for Canadian patients diagnosed with low-risk DTC, we developed this consensus statement by collecting feedback from a multidisciplinary team led by one chairperson (endocrinologist), an additional eight endocrinologists, two surgeons, and one patient partner. This consensus statement reflects current evidence and expert opinion regarding initial management and long-term surveillance of low-risk DTC patients. This work is valuable to Canadian thyroid practitioners as it provides standardized guidelines to ensure optimal care and improved outcomes for low-risk DTC patients.Keywords
Funding Information
- Canadian Society of Endocrinology and Metabolism
This publication has 82 references indexed in Scilit:
- Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification SystemsThyroid®, 2013
- Iodine or Not (IoN) for Low-risk Differentiated Thyroid Cancer: The Next UK National Cancer Research Network Randomised Trial following HiLoClinical Oncology, 2012
- Prognosis of low-risk papillary thyroid carcinoma patients: Its relationship with the size of primary tumorsEndocrine Journal, 2012
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging SystemThyroid®, 2010
- Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid CancerThyroid®, 2010
- Micrometastases in thyroid cancer. An important finding?Surgical Oncology, 2008
- Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2007
- Comparative Evaluation of Recombinant Human Thyrotropin-Stimulated Thyroglobulin Levels,131I Whole-Body Scintigraphy, and Neck Ultrasonography in the Follow-Up of Patients with Papillary Thyroid Microcarcinoma Who Have Not Undergone Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial DiagnosisThe Journal of Clinical Endocrinology & Metabolism, 2005